HighTide Therapeutics places big IPO bet on “affluenza” drug
The company is pouring almost all its R&D budget into producing a metabolic drug to treat several conditions including diabetes Key Takeaways: With no products yet on the market, HighTide…
Recent Articles
RELATED ARTICLES
-
Innogen Pharma jostles for a slice of the weight-loss market
- PegBio aims to bulk up its finances to deliver weight-loss drugs
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- IPO pitch puts BrainAurora’s earnings under the microscope
